Vaccine

GenBio AI Releases Phase 1 of World’s First Digital Organism to Transform Medical Research

PALO ALTO, Calif., Dec. 19, 2024 /PRNewswire/ -- Just as the transistor and microscope unlocked new waves of discovery, today,…

1 year ago

Black Book Market Research Releases Global Survey Findings on Population Health Applications in Emerging Markets

LONDON, UNITED KINGDOM / ACCESSWIRE / December 19, 2024 / Black Book Market Research, a leading global healthcare technology research…

1 year ago

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration…

1 year ago

Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

- Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies…

1 year ago

ENA Respiratory Announces Peer-Reviewed Publication of First Time in Humans and Influenza Virus Challenge Studies with the Intranasal Innate Immunomodulator INNA-051

When compared to placebo, prophylactic administration of INNA-051 was associated with significantly increased expression of multiple host defense genes and…

1 year ago

March of Dimes Awards Dr. Dennis Lo the 2025 March of Dimes Richard B. Johnston, Jr., MD Prize

Recognized for discovery of cell-free fetal DNA in maternal blood and creation of noninvasive prenatal testing (NIPT), used by as…

1 year ago

BioVaxys Secures GMP-Grade Lipid Supply for Production of DPX-Based Vaccines in Advance of Preclinical and Clinical Program Ramp-Up

VANCOUVER, BC, Dec. 17, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company")…

1 year ago

FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera

World Health Organization (WHO) has classified the global resurgence of cholera at the highest internal level for emergencies; 1.3 to…

1 year ago

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

ROCHESTER, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company…

1 year ago